Semaglutide's striking obesity results a fillip for Novo Nordisk

19 March 2018

Novo Nordisk (NOV: N) has presented plenty of evidence to show the effectiveness of semaglutide in diabetes, but that might not be the only widespread chronic disease where it can help patients.

Striking new results showing its impact in encouraging weight loss have been presented by the Danish pharma major from a Phase II, 52-week double blind dose-ranging study of once-daily semaglutide versus placebo and liraglutide as active control.

"In the USA alone, more than 90 million adults have obesity"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK